The bulk CD4+ CTLs in our cultures included large numbers of naïve T cells, whose cytolytic activity potential was significantly enhanced after CTLA-4 blockade with checkpoint inhibitors in a mouse model of combined immunotherapy for melanoma [27]. The gene discussed is CD4; the disease is melanoma.